Effects of atorvastatin on higher functions

European Journal of Clinical Pharmacology

Volumn 62, Issue 4, 2006, Pages 259-265

  Parale, G P ^a   Baheti, N N ^a   Kulkarni, P M ^a   Panchal, N V ^b  

^a Department of Medicine   (India)

^b Spandan Cardiac Diagnostic Centre ^*  (India)

Author keywords

Atorvastatin; Memory; MMSE; Neurocognitive tests; Statins

Indexed keywords

ATORVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATTENTION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL ASSESSMENT; COGNITION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFECT; EDUCATION; FEMALE; GEOGRAPHY; HEARING ACUITY; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMOTOR ACTIVITY; SEX RATIO; STATISTICAL ANALYSIS; WORKING MEMORY;

CARDIOVASCULAR DISEASES; COGNITION; FEMALE; HEPTANOIC ACIDS; HUMANS; INTELLIGENCE TESTS; MALE; MENTAL PROCESSES; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 33645662474     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0073-z     Document Type: Article

References (43)

1. Beatrice A, Golomb MH (2004) Conceptual foundations of UCSD Statin Study. Arch Int Med 164:153-162
2. Benton D (1995) Do cholesterol levels slow mental processing? Psychosom Med 57:50-53
3. Cattin L, Bordin P, Fonda M et al (1997) Factors associated with cognitive impairment among older Italian inpatients. J Am Geriatr Soc 45:1324-1330
4. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C (1995) Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolemia. Br J Clin Pharmacol 39:333-336
5. Davidson MH (2001) Safety profiles for the HMG Co-A reductase inhibitors: treatment and trust. Drugs 61:197-206
6. Dales MJM (2000) Statination. Intern Med News 1:55-56
7. Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12:105-112
8. England JD, Viles A, Walsh JC, Stewart PM (1999) Muscle side effects associated with simvastatin therapy. Med J Aust 153:562-563
9. Fassbender K, Simons M, Bergmann C, Stroick M et al (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861
10. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
11. Friedewald WT, Levy RI, Friedrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18(6)499-502
12. Golomb BA (1998) Cholesterol and violence: is there a connection? Ann Intern Med 128:478-487
13. Grobbee ED, Bots LM (2003) Statin treatment and progression of atherosclerotic plaque burden. Drugs 63(9):893-911
14. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP (2002) The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 57(7):M414-M418
15. Harrison RWS, Ashton CH (1994) Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 37(3):231-236
16. Houx PJ, Shepherd J, Blauw GJ et al (2002) Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry 73(4):385-389
17. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356(9242):1627-1631
18. King DS, Wilburn AJ, Wofford MR et al (2003) Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 23(12):1663-1667
19. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM10. Proc Natl Acad Sci USA 98:5815-5820
20. Krysiak R, Okopie B, Herman SZ (2003) Statin treatment and progression of atherosclerotic plaque burden. Drugs 63(9):893-911
21. Laufs U, Bohm M, Gertz K et al (2002) The hydrophilic HMG-CoA reductase inhibitor rosuvastatin regulates endothelial NO synthase and ischaemic stroke in vivo. Circulation 106(19 suppl):1272
22. Lewis RF, Rennick PM (1979) Manual for repeatable cognitive perceptual motor battery. Axon, Clinton, MI
23. Mason RP, Herbette LG, Silverman DI (1991) Can altering serum cholesterol affect neurologic functions? J Mol Cell Cardiol 23:1339-1342
24. Muldoon MF, Barger SD, Ryan CM et al (2000) Effects of lovastatin on cognitive function and psychological well-being. Am J Med 108:538-546
25. Muldoon MF, Flory JD, Ryan CM (2000) Serum cholesterol, the brain and cognitive functioning. In: Waldstein SR, Elias MF (eds) Neuropsychology of cardiovascular disease. Lawrence Erlbaum Associates, Mahwah, NJ
26. Nangle MR, Cotter MA, Cameron NE (2003) Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpora cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 52(9):2396-2402
27. Orsi A, Sherman O, Woldeselassie Z (2001) Simvastatin-associated memory loss. Pharmacotherapy 21(6):767-769
28. Raggat JL, Partridge CN (2002) HMG CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs 62(15):2185-2191
29. Reitan RM, Wolfson D (1993) The Halstead-Reitan neuropsychological test battery. Theory and clinical interpretation, 2nd edn. Neuropsychological Press, Tucson AZ
30. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly. Arch Neurol 59(2):223-227
31. Rose GA, Blackburn H, Gillum RF, Prineas RJ (1982) Cardiovascular survey methods, 2nd edn. (WHO Monograph Series no. 56 vol 1) WHO, Geneva
32. Waldstein SR, Jennings, JR, Ryan CM et al (1996) Hypertension and neuropsychological performance in man: interactive effects of age. Health Psychol 15:102-109
33. Ryman A (1994) Cholesterol, violent death and mental disorder. BMJ 309:421-422
34. Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
35. Simons M, Schwarzler F, Lutjohann D et al (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52:346-350
36. Sparks DL, Connor DJ, Browne PJ et al (2002) HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J Nutr Health Aging 6:323-324
37. Spreen O, Strauss E (1991) A compendium of neuropsychological tests. Administration, norms, and commentary. Oxford University Press, New York
38. Stalker TJ, Lefer AM, Scalia R (2001) A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvasculature endothelium: the role of mevalonic acid. Br J Pharmacol 133(3):406-412
39. Wagstaff LR, Mitton MW, Arvik BM et al (2003) Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23(7):871-880
40. Wechsler D (1997) Wechsler Adult Intelligence Scale, 3rd edn. Psychological Corporation, San Antonio, TX
41. Wehr H, Parnowski T, Puzynski S et al (1996) Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Age Ageing 15:267-270
42. Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443
43. Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59(3):378-384